OncoAlert and ecancer weekly round up for July 1- July 10, 2021
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
13 Jul 2021
ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B...
Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA
12 Jul 2021
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethaso...
Prof Thierry Facon - Chu De Lille, Lille, France
25 Jun 2021
The clinical value of maintenance in multiple myeloma
Prof Wee Joo Chng - National University of Singapore, Singapore
25 Jun 2021
Once weekly selinexor, carfilzomib, and dexamethasone (XKD) in carfilzomib non-r...
Prof Cristina Gasparetto - Duke Cancer Institute, Durham, USA
25 Jun 2021
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
25 Jun 2021
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refract...
Dr Claudio Cerchione - IRCCS, Meldola, Italy
23 Jun 2021
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hod...
Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
22 Jun 2021
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refracto...
Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA
21 Jun 2021
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previ...
Dr John Byrd - The Ohio State University, Columbus, USA
21 Jun 2021
CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL
Prof John Allan - Weill Cornell Medicine, New York, USA
17 Jun 2021
Interim results of a phase II study of blinatumomab plus ponatinib for Philadelp...
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
17 Jun 2021
